Anebulo Pharmaceuticals, Inc. (ANEB) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/8/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Powerful Philippine quake leaves at least 32 feared dead, survivors recount fear
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
February 10, 2023 8:38 AM ESTAUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the Company or Anebulo), today announced financial results for the three months ended December 31, 2022 and recent updates.
Second Quarter Fiscal Year 2023 and Subsequent Highlights:
Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evaluating ANEB-001s potential in treating acute cannabinoid intoxication (ACI). Preliminary data showed that a single 10 mg oral dose of ANEB-001 reduced key symptoms... More